Summary
0.16 0.00(3.08%)05/20/2024
Biolase Inc (BIOL)
Biolase Inc (BIOL)
Key Facts
| 1 Day | 1 Week | 1 Month | 3 Months | 6 Months | 1 Year | 5 Years | All Time |
| -0.94 | 13.55 | 14.64 | -54.49 | -89.34 | -99.20 | -100.00 | -100.00 |
Last 730 data points are shown. To view all data, Upgrade to PRO plan with only $1
| Trading Data | ||
| Close | 0.17 | |
| Open | 0.17 | |
| High | 0.17 | |
| Low | 0.16 | |
| Volume | 977,585 | |
| Change | -0.00 | |
| Change % | -0.94 | |
| Avg Volume (20 Days) | 1,091,123 | |
| Volume/Avg Volume (20 Days) Ratio | 0.90 | |
| 52 Week Range | 0.13 - 32.00 | |
| Price vs 52 Week High | -99.47% | |
| Price vs 52 Week Low | 29.54% | |
| Range | -0.71 | |
| Gap Up/Down | -0.02 | |
Fundamentals | ||
| Market Capitalization (Mln) | 5 | |
| EBIDTA | -13,939,000 | |
| PE Ratio | 0.0000 | |
| PEG Ratio | -0.2200 | |
| WallStreet Target Price | 11.22 | |
| Book Value | -0.0720 | |
| Earnings Per Share | -29.4400 | |
| EPS Estimate Current Quarter | -2.5500 | |
| EPS Estimate Next Quarter | -0.8900 | |
| EPS Estimate Current Year | -0.3200 | |
| EPS Estimate Next Year | -0.1100 | |
| Diluted EPS (TTM) | -29.4400 | |
| Revenues | ||
| Profit Marging | -0.4197 | |
| Operating Marging (TTM) | -0.3466 | |
| Return on asset (TTM) | -0.2855 | |
| Return on equity (TTM) | -6.0283 | |
| Revenue TTM | 49,164,000 | |
| Revenue per share TTM | 38.4690 | |
| Quarterly Revenue Growth (YOY) | -0.0400 | |
| Quarterly Earnings Growth (YOY) | 0.0000 | |
| Gross Profit (TTM) | 16,529,000 | |
| Dividends | ||
| Dividend Share | 0.0000 | |
| Dividend Yield | ||
| Valuations | ||
| Trailing PE | 0.0000 | |
| Forward PE | 0.0000 | |
| Price Sales (TTM) | 0.0000 | |
| Price Book (MRQ) | 0.7658 | |
| Revenue Enterprise Value | 0.3267 | |
| EBITDA Enterprise Value | -1.0400 | |
| Shares | ||
| Shares Outstanding | 33,256,900 | |
| Shares Float | 32,396,080 | |
| Shares Short | 0 | |
| Shares Short (Prior Month) | 0 | |
| Shares Ratio | 0.00 | |
| Short Outstanding (%) | 0.00 | |
| Short Float (%) | 0.01 | |
| Insider (%) | 0.33 | |
| Institutions (%) | 8.05 | |
05/13 22:28 EST - seekingalpha.com
BIOLASE, Inc. (BIOL) Q1 2024 Earnings Call Transcript
BIOLASE, Inc. (NASDAQ:BIOL ) Q1 2024 Earnings Conference Call May 13, 2024 4:30 PM ET Company Participants Michael Polyviou - Investor Relations John Beaver - President and Chief Executive Officer Jennifer Bright - Chief Financial Officer Conference Call Participants Bruce Jackson - Benchmark Company Ed Woo - Ascendiant Capital Operator Good day, and welcome to the BIOLASE First Quarter 2024 Results Conference Call. All participants will be in a listen-only mode.
BIOLASE, Inc. (BIOL) Q1 2024 Earnings Call Transcript
BIOLASE, Inc. (NASDAQ:BIOL ) Q1 2024 Earnings Conference Call May 13, 2024 4:30 PM ET Company Participants Michael Polyviou - Investor Relations John Beaver - President and Chief Executive Officer Jennifer Bright - Chief Financial Officer Conference Call Participants Bruce Jackson - Benchmark Company Ed Woo - Ascendiant Capital Operator Good day, and welcome to the BIOLASE First Quarter 2024 Results Conference Call. All participants will be in a listen-only mode.
05/13 16:05 EST - accesswire.com
Biolase Reports 2024 First Quarter Results; Reiterates Full-Year 2024 Guidance For Revenue Growth and Profitability
Increased Adoption of Dental Lasers and Improved Cost Structure Position Company for Sustained Long Term Growth and Success LAKE FOREST, CA / ACCESSWIRE / May 13, 2024 / BIOLASE, Inc. (NASDAQ:BIOL), a leader in dental laser technology, today reported its financial results for the first quarter ended March 31, 2024. First Quarter Financial Highlights Generated increased adoption of its industry-leading laser, with approximately 67% of U.S. Waterlase sales coming from new customers and approximately 42% from dental specialists Third strongest consumable sales quarter in company history, with consumable sales increasing 14% year over year, largely driven by over 600 subscriptions Gross margin was relatively flat compared to the year-ago quarter; however, it improved by 1% year over year as the Company continues to benefit from 100% of its trunk fiber requirements now being supplied in-house and improved by 7% compared to the prior quarter from inventory adjustments and reserve charges recorded in the fourth quarter ended December 31, 2023 Significantly lowered Adjusted EBITDA loss by 21% versus the same quarter last year, as cost reduction initiatives achieved desired outcomes Full Year 2024 Financial Guidance Reiterates 2024 full-year financial guidance, in which it expects: 2024 full-year net revenue to increase between 6% and 8% year over year to between $52 million and $53 million.
Biolase Reports 2024 First Quarter Results; Reiterates Full-Year 2024 Guidance For Revenue Growth and Profitability
Increased Adoption of Dental Lasers and Improved Cost Structure Position Company for Sustained Long Term Growth and Success LAKE FOREST, CA / ACCESSWIRE / May 13, 2024 / BIOLASE, Inc. (NASDAQ:BIOL), a leader in dental laser technology, today reported its financial results for the first quarter ended March 31, 2024. First Quarter Financial Highlights Generated increased adoption of its industry-leading laser, with approximately 67% of U.S. Waterlase sales coming from new customers and approximately 42% from dental specialists Third strongest consumable sales quarter in company history, with consumable sales increasing 14% year over year, largely driven by over 600 subscriptions Gross margin was relatively flat compared to the year-ago quarter; however, it improved by 1% year over year as the Company continues to benefit from 100% of its trunk fiber requirements now being supplied in-house and improved by 7% compared to the prior quarter from inventory adjustments and reserve charges recorded in the fourth quarter ended December 31, 2023 Significantly lowered Adjusted EBITDA loss by 21% versus the same quarter last year, as cost reduction initiatives achieved desired outcomes Full Year 2024 Financial Guidance Reiterates 2024 full-year financial guidance, in which it expects: 2024 full-year net revenue to increase between 6% and 8% year over year to between $52 million and $53 million.
05/06 06:30 EST - accesswire.com
BIOLASE to Report First Quarter 2024 Results on May 13, 2024
LAKE FOREST, CA / ACCESSWIRE / May 6, 2024 / BIOLASE, Inc. (NASDAQ:BIOL), the globally recognized leader in dental laser technology, today announced that it will release first quarter 2024 financial and operating results on Monday, May 13, 2024, after the close of the U.S. financial markets and will host a conference call and webcast that day at 4:30 p.m. ET / 1:30 p.m.
BIOLASE to Report First Quarter 2024 Results on May 13, 2024
LAKE FOREST, CA / ACCESSWIRE / May 6, 2024 / BIOLASE, Inc. (NASDAQ:BIOL), the globally recognized leader in dental laser technology, today announced that it will release first quarter 2024 financial and operating results on Monday, May 13, 2024, after the close of the U.S. financial markets and will host a conference call and webcast that day at 4:30 p.m. ET / 1:30 p.m.
03/21 18:35 EST - seekingalpha.com
BIOLASE, Inc. (BIOL) Q4 2023 Earnings Call Transcript
BIOLASE, Inc. (BIOL) Q4 2023 Earnings Call Transcript
BIOLASE, Inc. (BIOL) Q4 2023 Earnings Call Transcript
BIOLASE, Inc. (BIOL) Q4 2023 Earnings Call Transcript
03/21 16:05 EST - accesswire.com
Biolase Reports Full-Year 2023 Results; Expects Continued Revenue Growth In 2024
LAKE FOREST, CA / ACCESSWIRE / March 21, 2024 / BIOLASE, Inc. (NASDAQ:BIOL), the globally recognized leader in dental laser technology, who previously announced its preliminary financial results for the fourth quarter and full year ended December 31, 2023, today reported its financial results for the quarter and full year. 2023 Full-Year Highlights Achieved revenue growth despite industry headwinds and a challenging interest rate environment throughout 2023.
Biolase Reports Full-Year 2023 Results; Expects Continued Revenue Growth In 2024
LAKE FOREST, CA / ACCESSWIRE / March 21, 2024 / BIOLASE, Inc. (NASDAQ:BIOL), the globally recognized leader in dental laser technology, who previously announced its preliminary financial results for the fourth quarter and full year ended December 31, 2023, today reported its financial results for the quarter and full year. 2023 Full-Year Highlights Achieved revenue growth despite industry headwinds and a challenging interest rate environment throughout 2023.
03/14 06:30 EST - accesswire.com
BIOLASE to Report Fourth Quarter and Full Year 2023 Results on March 21, 2024
LAKE FOREST, CA / ACCESSWIRE / March 14, 2024 / BIOLASE, Inc. (NASDAQ:BIOL), the globally recognized leader in dental laser technology, today announced that it will release fourth quarter and full year 2023 financial and operating results on Thursday, March 21, 2024, after the close of the U.S. financial markets and will host a conference call and webcast that day at 4:30 p.m. ET / 1:30 p.m.
BIOLASE to Report Fourth Quarter and Full Year 2023 Results on March 21, 2024
LAKE FOREST, CA / ACCESSWIRE / March 14, 2024 / BIOLASE, Inc. (NASDAQ:BIOL), the globally recognized leader in dental laser technology, today announced that it will release fourth quarter and full year 2023 financial and operating results on Thursday, March 21, 2024, after the close of the U.S. financial markets and will host a conference call and webcast that day at 4:30 p.m. ET / 1:30 p.m.
02/22 06:30 EST - accesswire.com
Biolase Launches State-of-the-Art All-Tissue Laser System To Accelerate Adoption of Lasers in Dentistry
Waterlase iPlus Premier Edition™ is being unveiled at the Chicago Midwinter Meeting 2024 LAKE FOREST, CA / ACCESSWIRE / February 22, 2024 / BIOLASE, Inc. (NASDAQ:BIOL), the globally recognized leader in dental laser technology, has launched its state-of-the-art all-tissue laser system, Waterlase iPlus Premier Edition™, and will be debuting it at the Chicago Midwinter Meeting 2024 from February 22nd to 24th at booth 4608. The Waterlase iPlus Premier Edition™ is an extraordinary update to the industry-leading Waterlase iPlus and represents the pinnacle of innovation in dental care.
Biolase Launches State-of-the-Art All-Tissue Laser System To Accelerate Adoption of Lasers in Dentistry
Waterlase iPlus Premier Edition™ is being unveiled at the Chicago Midwinter Meeting 2024 LAKE FOREST, CA / ACCESSWIRE / February 22, 2024 / BIOLASE, Inc. (NASDAQ:BIOL), the globally recognized leader in dental laser technology, has launched its state-of-the-art all-tissue laser system, Waterlase iPlus Premier Edition™, and will be debuting it at the Chicago Midwinter Meeting 2024 from February 22nd to 24th at booth 4608. The Waterlase iPlus Premier Edition™ is an extraordinary update to the industry-leading Waterlase iPlus and represents the pinnacle of innovation in dental care.
02/20 06:30 EST - accesswire.com
Biolase Announces First Quarter 2024 Webinar Series 'Lets Talk Dental'
LAKE FOREST, CA / ACCESSWIRE / February 20, 2024 / BIOLASE, Inc. (NASDAQ:BIOL), the global leader in dental lasers, remains committed to expanding its educational offerings through its web portal, enabling dental clinicians to elevate their standard of dental care and improve patient outcomes through laser technology. "Let's Talk Dental," a free webinar series focused on a variety of topics covering all dental disciplines, kicked off the year with a webinar on January 18, 2024, hosted by Dr. Paul Chang, a periodontist and prosthodontist with a private practice in McKinney, Texas.
Biolase Announces First Quarter 2024 Webinar Series 'Lets Talk Dental'
LAKE FOREST, CA / ACCESSWIRE / February 20, 2024 / BIOLASE, Inc. (NASDAQ:BIOL), the global leader in dental lasers, remains committed to expanding its educational offerings through its web portal, enabling dental clinicians to elevate their standard of dental care and improve patient outcomes through laser technology. "Let's Talk Dental," a free webinar series focused on a variety of topics covering all dental disciplines, kicked off the year with a webinar on January 18, 2024, hosted by Dr. Paul Chang, a periodontist and prosthodontist with a private practice in McKinney, Texas.
02/15 14:45 EST - accesswire.com
BIOLASE, Inc. Announces Closing of $7.0 Million Public Offering
LAKE FOREST, CA / ACCESSWIRE / February 15, 2024 / BIOLASE, Inc. (NASDAQ:BIOL), the global leader in dental lasers, today announced the closing of its public offering of 16,000,000 units, with each unit consisting of one share of common stock (or one pre-funded warrant to purchase one share of common stock), one Class A Warrant to purchase one share of common stock, and one Class B Warrant to purchase one share of common stock. Each unit was sold at an effective public offering price of $0.44.
BIOLASE, Inc. Announces Closing of $7.0 Million Public Offering
LAKE FOREST, CA / ACCESSWIRE / February 15, 2024 / BIOLASE, Inc. (NASDAQ:BIOL), the global leader in dental lasers, today announced the closing of its public offering of 16,000,000 units, with each unit consisting of one share of common stock (or one pre-funded warrant to purchase one share of common stock), one Class A Warrant to purchase one share of common stock, and one Class B Warrant to purchase one share of common stock. Each unit was sold at an effective public offering price of $0.44.
02/14 06:30 EST - accesswire.com
BIOLASE, Inc. Granted Extension by Nasdaq to Regain Compliance with the Stockholders' Equity Continued Listing Requirement
LAKE FOREST, CA / ACCESSWIRE / February 14, 2024 / BIOLASE, Inc. (NASDAQ:BIOL), the global leader in dental lasers, today announced that it received notice from the Staff of the Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") that the Staff has determined to grant the Company an extension of time to regain compliance with Listing Rule 5550(b) (the "Rule"). The Rule requires a minimum of $2,500,000 stockholders' equity, $35,000,000 market value of listed securities, or $500,000 net income from continuing operations.
BIOLASE, Inc. Granted Extension by Nasdaq to Regain Compliance with the Stockholders' Equity Continued Listing Requirement
LAKE FOREST, CA / ACCESSWIRE / February 14, 2024 / BIOLASE, Inc. (NASDAQ:BIOL), the global leader in dental lasers, today announced that it received notice from the Staff of the Listing Qualifications Department (the "Staff") of The Nasdaq Stock Market LLC ("Nasdaq") that the Staff has determined to grant the Company an extension of time to regain compliance with Listing Rule 5550(b) (the "Rule"). The Rule requires a minimum of $2,500,000 stockholders' equity, $35,000,000 market value of listed securities, or $500,000 net income from continuing operations.
02/13 09:15 EST - accesswire.com
BIOLASE, Inc. Announces Pricing of $7.0 Million Public Offering
LAKE FOREST, CA / ACCESSWIRE / February 13, 2024 / BIOLASE, Inc. (NASDAQ:BIOL), the global leader in dental lasers, today announced the pricing of its public offering of 16,000,000 units, with each unit consisting of one share of common stock (or one pre-funded warrant to purchase one share of common stock), one Class A Warrant to purchase one share of common stock, and one Class B Warrant to purchase one share of common stock. Each unit is being sold at an effective public offering price of $0.44.
BIOLASE, Inc. Announces Pricing of $7.0 Million Public Offering
LAKE FOREST, CA / ACCESSWIRE / February 13, 2024 / BIOLASE, Inc. (NASDAQ:BIOL), the global leader in dental lasers, today announced the pricing of its public offering of 16,000,000 units, with each unit consisting of one share of common stock (or one pre-funded warrant to purchase one share of common stock), one Class A Warrant to purchase one share of common stock, and one Class B Warrant to purchase one share of common stock. Each unit is being sold at an effective public offering price of $0.44.
02/09 08:35 EST - benzinga.com
Top 5 Health Care Stocks That Are Preparing To Pump In February - CNS Pharma (NASDAQ:CNSP), Biolase (NASDAQ:BIOL)
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
Top 5 Health Care Stocks That Are Preparing To Pump In February - CNS Pharma (NASDAQ:CNSP), Biolase (NASDAQ:BIOL)
The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.
01/29 06:30 EST - prnewswire.com
BIOLASE REPORTS UNAUDITED REVENUE GROWTH FOR FULL YEAR 2023 AND PROVIDES OUTLOOK FOR FULL YEAR 2024
Expects Continued Revenue Growth in 2024 and Takes Steps to Further Improve Operating Efficiency as the Company Pursues Profitability Goals LAKE FOREST, Calif. , Jan. 29, 2024 /PRNewswire/ --Â BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, announced preliminary unaudited revenue results for 2023 based on currently available information and expects to report year-over-year growth as it continues to generate interest among dental practitioners for its industry leading lasers.
BIOLASE REPORTS UNAUDITED REVENUE GROWTH FOR FULL YEAR 2023 AND PROVIDES OUTLOOK FOR FULL YEAR 2024
Expects Continued Revenue Growth in 2024 and Takes Steps to Further Improve Operating Efficiency as the Company Pursues Profitability Goals LAKE FOREST, Calif. , Jan. 29, 2024 /PRNewswire/ --Â BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, announced preliminary unaudited revenue results for 2023 based on currently available information and expects to report year-over-year growth as it continues to generate interest among dental practitioners for its industry leading lasers.
01/08 16:05 EST - prnewswire.com
BIOLASE ENHANCES EDUCATION OFFERINGS IN 2024 DUE TO INCREASING DEMAND OF DENTAL LASER COURSES THROUGHOUT 2023
Robust Educational Courses Commence with an Advanced Mastery Course on February 2–3, 2024 LAKE FOREST, Calif. , Jan. 8, 2024 /PRNewswire/ -- BIOLASE, Inc.  (NASDAQ: BIOL), the global leader in dental lasers, has experienced growing demand for its robust educational offering and as a result has increased the number of dental laser courses planned for the first quarter of 2024.
BIOLASE ENHANCES EDUCATION OFFERINGS IN 2024 DUE TO INCREASING DEMAND OF DENTAL LASER COURSES THROUGHOUT 2023
Robust Educational Courses Commence with an Advanced Mastery Course on February 2–3, 2024 LAKE FOREST, Calif. , Jan. 8, 2024 /PRNewswire/ -- BIOLASE, Inc.  (NASDAQ: BIOL), the global leader in dental lasers, has experienced growing demand for its robust educational offering and as a result has increased the number of dental laser courses planned for the first quarter of 2024.
01/03 16:05 EST - prnewswire.com
BIOLASE RECEIVES SECOND TOP WORKPLACES 2023 AWARD
LAKE FOREST, Calif. , Jan. 3, 2024 /PRNewswire/ -- BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced that the Company has been awarded a Top Workplaces 2023 Â honor by the Inland News Group.
BIOLASE RECEIVES SECOND TOP WORKPLACES 2023 AWARD
LAKE FOREST, Calif. , Jan. 3, 2024 /PRNewswire/ -- BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced that the Company has been awarded a Top Workplaces 2023 Â honor by the Inland News Group.
12/14 16:05 EST - prnewswire.com
BIOLASE RECEIVES TOP WORKPLACES 2023 AWARD
LAKE FOREST, Calif. , Dec. 14, 2023 /PRNewswire/ --Â BIOLASE, Inc. Â (NASDAQ: BIOL), the global leader in dental lasers, today announced it has been awarded a Top Workplaces 2023 honor by Orange County Register Top Workplaces.
BIOLASE RECEIVES TOP WORKPLACES 2023 AWARD
LAKE FOREST, Calif. , Dec. 14, 2023 /PRNewswire/ --Â BIOLASE, Inc. Â (NASDAQ: BIOL), the global leader in dental lasers, today announced it has been awarded a Top Workplaces 2023 honor by Orange County Register Top Workplaces.
12/12 16:05 EST - prnewswire.com
BIOLASE Successfully Concludes Waterlase iPlus All Tissue Laser Trial
Receives Overwhelmingly Positive Dentist Feedback and Unanimous Approval During Independently led Trial Results Demonstrate 100% Performance Satisfaction and Recommendation of Wider Adoption among Dental Practices LAKE FOREST, Calif. , Dec. 12, 2023 /PRNewswire/ -- BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced the successful completion of a trial program featuring the Waterlase iPlus All Tissue laser conducted by six leading U.S. dentists.
BIOLASE Successfully Concludes Waterlase iPlus All Tissue Laser Trial
Receives Overwhelmingly Positive Dentist Feedback and Unanimous Approval During Independently led Trial Results Demonstrate 100% Performance Satisfaction and Recommendation of Wider Adoption among Dental Practices LAKE FOREST, Calif. , Dec. 12, 2023 /PRNewswire/ -- BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, today announced the successful completion of a trial program featuring the Waterlase iPlus All Tissue laser conducted by six leading U.S. dentists.
12/06 13:46 EST - prnewswire.com
BIOLASE, Inc. Announces Pricing of $1.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
LAKE FOREST, Calif. , Dec. 6, 2023 /PRNewswire/ -- BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, announced today that it has entered into a securities purchase agreement with a single institutional investor to purchase approximately $1.4 million of its common stock and pre-funded warrants in a registered direct offering and warrants to purchase common stock in a concurrent private placement, priced at-the-market under Nasdaq rules.
BIOLASE, Inc. Announces Pricing of $1.4 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
LAKE FOREST, Calif. , Dec. 6, 2023 /PRNewswire/ -- BIOLASE, Inc. (NASDAQ: BIOL), the global leader in dental lasers, announced today that it has entered into a securities purchase agreement with a single institutional investor to purchase approximately $1.4 million of its common stock and pre-funded warrants in a registered direct offering and warrants to purchase common stock in a concurrent private placement, priced at-the-market under Nasdaq rules.
11/08 06:30 EST - prnewswire.com
Landmark Study Performed by the Independent McGuire Institute Confirms Positive 12 Month Clinical Outcomes for BIOLASE REPAIR® Perio Protocol
Validates  BIOLASE REPAIR® Perio Protocol is a Superior Alternative as it pertains to patient reported outcomes. LAKE FOREST, Calif.
Landmark Study Performed by the Independent McGuire Institute Confirms Positive 12 Month Clinical Outcomes for BIOLASE REPAIR® Perio Protocol
Validates  BIOLASE REPAIR® Perio Protocol is a Superior Alternative as it pertains to patient reported outcomes. LAKE FOREST, Calif.
09/18 16:30 EST - prnewswire.com
BIOLASE Inc. Announces Closing of $4.5 Million Underwritten Public Offering of Series J Convertible Redeemable Preferred Stock and Warrants
LAKE FOREST, Calif. , Sept. 18, 2023 /PRNewswire/ -- BIOLASE, Inc. (NASDAQ: BIOL) ("BIOLASE" or the "Company"), a global leader in dental lasers, today announced the closing of its previously announced underwritten public offering of 75,000 units (the "Units"), with each Unit consisting of one share of BIOLASE's Series J Convertible Redeemable Preferred Stock, par value $0.001 per share, with a liquidation preference of $100.00 per share (the "Series J Convertible Preferred Stock"), and one warrant (the "Warrants") to purchase one-half of one (0.50) share of Series J Convertible Preferred Stock.
BIOLASE Inc. Announces Closing of $4.5 Million Underwritten Public Offering of Series J Convertible Redeemable Preferred Stock and Warrants
LAKE FOREST, Calif. , Sept. 18, 2023 /PRNewswire/ -- BIOLASE, Inc. (NASDAQ: BIOL) ("BIOLASE" or the "Company"), a global leader in dental lasers, today announced the closing of its previously announced underwritten public offering of 75,000 units (the "Units"), with each Unit consisting of one share of BIOLASE's Series J Convertible Redeemable Preferred Stock, par value $0.001 per share, with a liquidation preference of $100.00 per share (the "Series J Convertible Preferred Stock"), and one warrant (the "Warrants") to purchase one-half of one (0.50) share of Series J Convertible Preferred Stock.